Pharma Universalis: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharma Universalis
Largest movements
- Cash +€58,918
up €58,918 (+111.6%), from €52,786 to €111,704
mainly Net result for the year (+€45,822) and Tax, wage and social debts (+€12,020)
- Deferred charges and accrued income +€2,370
new in 2025: €2,370
- Receivables within one year -€1,965
down €1,965 (-16.2%), from €12,100 to €10,135
- Tangible fixed assets -€1,339
down €1,339 (-21.2%), from €6,327 to €4,988
- Reserves +€45,822
up €45,822 (+105.1%), from €43,581 to €89,403
- Tax, wage and social debts +€12,020
up €12,020 (+55.5%), from €21,654 to €33,674
of which Taxes: +€12,004
- Gross operating margin +€2,302
up €2,302 (+4.0%), from €57,319 to €59,622
- Taxes +€768
up €768 (+6.7%), from €11,499 to €12,267
- Depreciation -€672
down €672 (-31.9%), from €2,104 to €1,432
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €71,306 | €129,198 | +€57,891 | +81.2% |
| Formation expenses | 20 | €94 | €0 | -€94 | -100.0% |
| Fixed assets | 21/28 | €6,327 | €4,988 | -€1,339 | -21.2% |
| Tangible fixed assets | 22/27 | €6,327 | €4,988 | -€1,339 | -21.2% |
| Furniture and vehicles | 24 | €6,327 | €4,988 | -€1,339 | -21.2% |
| Current assets | 29/58 | €64,886 | €124,209 | +€59,323 | +91.4% |
| Amounts receivable within one year | 40/41 | €12,100 | €10,135 | -€1,965 | -16.2% |
| Trade receivables | 40 | €12,100 | €10,135 | -€1,965 | -16.2% |
| Cash at bank and in hand | 54/58 | €52,786 | €111,704 | +€58,918 | +111.6% |
| Deferred charges and accrued income | 490/1 | - | €2,370 | +€2,370 | |
| Total equity and liabilities | 10/49 | €71,306 | €129,198 | +€57,891 | +81.2% |
| Equity | 10/15 | €48,581 | €94,403 | +€45,822 | +94.3% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €43,581 | €89,403 | +€45,822 | +105.1% |
| Distributable reserves | 133 | €43,581 | €89,403 | +€45,822 | +105.1% |
| Amounts payable | 17/49 | €22,725 | €34,795 | +€12,070 | +53.1% |
| Amounts payable within one year | 42/48 | €21,976 | €34,100 | +€12,124 | +55.2% |
| Trade debts | 44 | €68 | €39 | -€29 | -42.7% |
| Suppliers | 440/4 | €68 | €39 | -€29 | -42.7% |
| Taxes, remuneration and social security | 45 | €21,654 | €33,674 | +€12,020 | +55.5% |
| Taxes | 450/3 | €18,590 | €30,594 | +€12,004 | +64.6% |
| Remuneration and social security | 454/9 | €3,064 | €3,080 | +€16 | +0.5% |
| Other amounts payable | 47/48 | €254 | €386 | +€133 | +52.3% |
| Accrued charges and deferred income | 492/3 | €749 | €695 | -€54 | -7.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,104 | €1,432 | -€672 | -31.9% |
| Other operating charges | 640/8 | €106 | €0 | -€106 | -100.0% |
| Gross operating margin | 9900 | €57,319 | €59,622 | +€2,302 | +4.0% |
| Operating profit (loss) | 9901 | €55,110 | €58,190 | +€3,080 | +5.6% |
| Financial charges | 65/66B | €30 | €101 | +€71 | +237.7% |
| Recurring financial charges | 65 | €30 | €101 | +€71 | +237.7% |
| Profit (loss) for the period before taxes | 9903 | €55,080 | €58,088 | +€3,009 | +5.5% |
| Income taxes | 67/77 | €11,499 | €12,267 | +€768 | +6.7% |
| Profit (loss) for the period | 9904 | €43,581 | €45,822 | +€2,241 | +5.1% |
| Profit (loss) for the period to be appropriated | 9905 | €43,581 | €45,822 | +€2,241 | +5.1% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.